71 / 89
71
multicenter,
randomized,
double-blind,
placebo-controlled trial of oral type I collagen
treatment in patients with diffuse cutaneous
systemic sclerosis: I. oral type I collagen does
not improve skin in all patients, but may
improve skin in late-phase disease. Arthritis
Rheum 2008;58:1810-22.
37.
Kawald A, Burmester GR, Huscher D,
Sunderkötter C, Riemekasten G. Low versus
high-dose iloprost therapy over 21 days in
patients
with
secondary
Raynaud's
phenomenon and systemic sclerosis: a
randomized, open, single-center study. J
Rheumatol 2008;35:1830-7.
38.
Tashkin DP, Elashoff R, Clements PJ, Goldin J,
Roth MD, Furst DE, et al. Cyclophosphamide
versus placebo in scleroderma lung disease. N
Engl J Med 2006;354:2655-66.
39.
Clements PJ, Roth MD, Elashoff R, Tashkin DP,
Goldin J, Silver RM, et al. Scleroderma lung
study (SLS): differences in presentation and
course of patients with limited versus diffuse
systemic sclerosis. Ann Rheum Dis
2007;66:1641-7.
40.
Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A
prospective
observational
study
of
mycophenolate mofetil treatment in progressive
diffuse cutaneous systemic sclerosis of recent
onset. J Rheumatol 2012;39:1241-7.
41.
Daoussis D, Liossis SN, Tsamandas AC,
Kalogeropoulou C, Kazantzi A, Sirinian C, et al.